A Phase 3 interventional study of Tadalafil and Placebo in Erectile Dysfunction and Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 52 sites in 9 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2011-07-28.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.
Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 9th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2009, is one of 19 in phase 3, and was the 24th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Surgical Outcomes Research Centre (SOuRCe) · Sites in Australia
Ages 18+ · Men only
Al-Azhar University · Sites in Egypt
Ages 18–70 · Men only
Beni-Suef University · Sites in Egypt
Ages 30–70 · Men only
Mansoura University · Sites in Egypt
Ages 21+ · Men only
Aswan University Hospital · Sites in Egypt
Ages 21+ · Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 21 · Phase 4 26
First in 2002; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 606 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 199 across the 56 interventional studies. Of the 42 that completed or were terminated, 13 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 57 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
28 studies in Erectile Dysfunction by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 28 finished, 14 (50%) have results posted.
Among the 28 studies in Erectile Dysfunction by Eli Lilly and Company, this one is the 8th largest by enrollment, is one of 4 that started in 2009, is one of 13 in phase 3, and was the 19th registered.
Eli Lilly and Company’s Erectile Dysfunction studies by the year they started, since 2002.
3 of the studies testing tadalafil in Erectile Dysfunction that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07642505Beni-Suef UniversityL-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction | 2026-11 |
| NCT07391579Mansoura UniversityDaily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients | 2026-12 |
| NCT07753720Al-Azhar UniversityDaily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies testing tadalafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 28 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study LVHR is a Phase 3 study which will examine the efficacy and safety of tadalafil 2.5 and 5 mg once daily versus placebo for the treatment of erectile dysfunction (ED) and signs and symptoms of benign prostatic hyperplasia (BPH) in men with both ED and signs and symptoms of BPH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tadalafil
Drug: Tadalafil
Drug: Placebo
tablet once daily by mouth for 12 weeks.
Also known as: Cialis, LY450190
Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 Endpoint (5 mg)
The total IPSS is obtained by combining the scores of the responses to component questions 1 through 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score at Week 12 Endpoint (5 mg)
Self-reported erectile function over the past 4 weeks. Questions 1-5 were scored from 0-5, and Question 15 from 1 to 5. Erectile Function Domain scores range from 1 to 30; lower numerical scores represent greater severity of erectile dysfunction. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 Endpoint (2.5 mg)
The total IPSS is obtained by combining the scores of the responses to component questions 1 through 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score at Week 12 Endpoint (2.5 mg)
Self-reported erectile function over the past 4 weeks. Questions 1-5 were scored from 0-5, and Question 15 from 1 to 5. Erectile Function Domain scores range from 1 to 30; lower numerical scores represent greater severity of erectile dysfunction. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 3 at Week 12 Endpoint (5 mg)
Assessed as the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3, "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of Yes responses per the number of sexual attempts for a participant during a study period. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in Benign Prostatic Hyperplasia (BPH) Impact Index (BII) at Week 12 Endpoint (5 mg)
The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 3 at Week 12 Endpoint (2.5 mg)
Assessed as the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3, "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of yes responses per the number of sexual attempts for a participant during a study period. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in BPH Impact Index (BII) at Week 12 Endpoint (2.5 mg)
The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in Modified IPSS (mIPSS) at Week 2 Endpoint
The Modified IPSS is the total IPSS collected at 2 weeks post-baseline. The total IPSS is obtained by combining the scores of the responses to component questions 1 through 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from ANCOVA. The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 2 weeks
Change From Baseline in International Prostate Symptom Score (IPSS) at Week 4 and Week 8 Endpoint
The total IPSS is obtained by combining the scores of the responses to component questions 1 through 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 4 weeks, 8 weeks
Change From Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain at Week 4 and Week 8 Endpoint
Self-reported erectile function over the past 4 weeks. Questions 1-5 were scored from 0-5, and Question 15 from 1 to 5. Erectile Function Domain scores range from 1 to 30; lower numerical scores represent greater severity of erectile dysfunction. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 4 weeks, 8 weeks
Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 3 at Week 4 and Week 8 Endpoint
Assessed as the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3, "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of yes responses per the number of sexual attempts for a participant during a study period. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 4 weeks, 8 weeks
Change From Baseline in BPH Impact Index (BII) at Week 4 and 8 Endpoint
The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 4 weeks, 8 weeks
Change From Baseline in International Prostate Symptom Score Voiding (Obstructive) Subscore at Week 12 Endpoint
IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. The obstructive subscore ranges from 0 to 20 with a higher score representing greater obstruction. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in International Prostate Symptom Score Storage (Irritative) Subscore at Week 12 Endpoint
IPSS irritative subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. The irritative subscore ranges from 0 to 15 with a higher score representing more irritative symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in International Prostate Symptom Score Nocturia Question at Week 12
The IPSS Nocturia question (Question 7) measures the number of times needed to get up at night to urinate. Scores range from 0 (none) to 5 (5 or more times). Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in International Prostate Symptom Score Quality of Life (QoL) at Week 12 Endpoint
Assessment of quality of life (QoL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible). Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in International Index of Erectile Function - Overall Satisfaction Domain at Week 12 Endpoint
Self-reported overall satisfaction over the past 4 weeks. Calculated as the sum of IIEF Questions 13 and 14. Each question is scored from 1 through 5, with a possible total score of 2 through 10. Higher scores represent greater satisfaction. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in International Index of Erectile Function - Intercourse Satisfaction Domain at Week 12 Endpoint
Self-reported intercourse satisfaction over the past 4 weeks. Calculated as the sum of IIEF Questions 6, 7 and 8. Each question is scored from 0 through 5 with a possible total score of 0 through 15. Higher score represent greater satisfaction. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in International Index of Erectile Function Question 3 at Week 12 Endpoint
IIEF Question 3 asks how often a subject was able to penetrate his partner over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in International Index of Erectile Function Question 4 at Week 12 Endpoint
IIEF Question 4 asks whether how often a subject was able to maintain an erection after penetration over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 2 at Week 12 Endpoint
Assessed as the mean change from baseline in the percentage of Yes responses to the SEP diary Question 2, "Were you able to insert your penis into your partner's vagina?" Data are presented as the mean percentage of yes responses per the number of sexual attempts for a participant during a study period. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 4 at Week 12 Endpoint
Assessed as the mean change from baseline in the percentage of Yes responses to the SEP diary Question 4, "Were you satisfied with the hardness of your erection?" Data are presented as the mean percentage of yes responses per the number of sexual attempts for a participant during a study period. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 5
Assessed as the mean change from baseline in the percentage of Yes responses to the SEP diary Question 5, "Were you satisfied overall with this sexual experience?" Data are presented as the mean percentage of yes responses per the number of sexual attempts for a participant during a study period. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Patient Global Impression of Improvement (PGI-I) at Week 12 Endpoint
A scale that measures the patient's perception of urinary symptoms at endpoint compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the seven categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).
Time frame: 12 weeks
Clinician Global Impression of Improvement (CGI-I) at Week 12 Endpoint
A scale that measures clinician's rating of the total change in the patient's urinary symptoms at endpoint compared with the start of treatment. Scores range from 1 (very much better) to 7 (very much worse).The data are presented as the number of participants in each of the seven categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).
Time frame: 12 weeks
Erectile Function General Assessment Questionnaire (EF-GAQ)
The EF-GAQ consisted of two questions: (1) Has the treatment you have been taking during this study improved your erections? and (2) If yes, has the treatment improved your ability to engage in sexual activity? Each question has a Yes/No response.
Time frame: 12 weeks
Change From Baseline in Uroflowmetry Parameters - Peak Urine Flow Rate (Qmax) at Week 12 Endpoint
Qmax is defined as the peak urine flow rate (measured in milliliters per second \[mL/sec\] using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 milliliters (mL) and the voided volume (Vcomp) was \>= 125 mL.
Time frame: Baseline, 12 weeks
Change From Baseline in Uroflowmetry Parameters - Mean Urine Flow Rate (Qmean) at Week 12 Endpoint
Qmean is defined as the average urine flow rate (measured in milliliters per second \[mL/second\] using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 milliliters (mL) and the voided volume (Vcomp) was \>= 125 mL.
Time frame: Baseline, 12 weeks
Change From Baseline in Uroflowmetry Parameters - Voided Volume (Vcomp) at Week 12 Endpoint
Vcomp is defined as the volume of urine voided (measures in mL using a standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 milliliters (mL) and the voided volume (Vcomp) was \>= 125 mL.
Time frame: Baseline, 12 weeks
| Milestone | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Started | 198 | 208 | 200 |
| Completed | 172 | 184 | 170 |
| Not completed | 26 | 24 | 30 |
| Withdrew: Adverse event | 2 | 6 | 3 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 3 | 8 |
| Withdrew: Lost to follow-up | 1 | 3 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Protocol violation | 6 | 2 | 6 |
| Withdrew: Entry criteria not met | 8 | 6 | 3 |
| Withdrew: Withdrawal by subject | 7 | 4 | 8 |
The total IPSS is obtained by combining the scores of the responses to component questions 1 through 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 5 mg | Placebo |
|---|---|---|
| Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 Endpoint (5 mg) | -6.1 ± 0.43 | -3.8 ± 0.45 |
Self-reported erectile function over the past 4 weeks. Questions 1-5 were scored from 0-5, and Question 15 from 1 to 5. Erectile Function Domain scores range from 1 to 30; lower numerical scores represent greater severity of erectile dysfunction. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 5 mg | Placebo |
|---|---|---|
| Change From Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score at Week 12 Endpoint (5 mg) | 6.5 ± 0.49 | 1.8 ± 0.51 |
The total IPSS is obtained by combining the scores of the responses to component questions 1 through 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Placebo |
|---|---|---|
| Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 Endpoint (2.5 mg) | -4.6 ± 0.44 | -3.8 ± 0.45 |
Self-reported erectile function over the past 4 weeks. Questions 1-5 were scored from 0-5, and Question 15 from 1 to 5. Erectile Function Domain scores range from 1 to 30; lower numerical scores represent greater severity of erectile dysfunction. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Placebo |
|---|---|---|
| Change From Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score at Week 12 Endpoint (2.5 mg) | 5.2 ± 0.5 | 1.8 ± 0.51 |
Assessed as the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3, "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of Yes responses per the number of sexual attempts for a participant during a study period. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| percentage of Yes responses | Tadalafil 5 mg | Placebo |
|---|---|---|
| Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 3 at Week 12 Endpoint (5 mg) | 31.7 ± 2.07 | 12.0 ± 2.14 |
The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on scale | Tadalafil 5 mg | Placebo |
|---|---|---|
| Change From Baseline in Benign Prostatic Hyperplasia (BPH) Impact Index (BII) at Week 12 Endpoint (5 mg) | -2.1 ± 0.19 | -1.2 ± 0.20 |
Assessed as the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3, "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of yes responses per the number of sexual attempts for a participant during a study period. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| percentage of yes responses | Tadalafil 2.5 mg | Placebo |
|---|---|---|
| Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 3 at Week 12 Endpoint (2.5 mg) | 24.6 ± 2.11 | 12.0 ± 2.14 |
The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Placebo |
|---|---|---|
| Change From Baseline in BPH Impact Index (BII) at Week 12 Endpoint (2.5 mg) | -1.6 ± 0.20 | -1.2 ± 0.20 |
The Modified IPSS is the total IPSS collected at 2 weeks post-baseline. The total IPSS is obtained by combining the scores of the responses to component questions 1 through 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from ANCOVA. The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Modified IPSS (mIPSS) at Week 2 Endpoint | -2.8 ± 0.39 | -4.0 ± 0.38 | -2.2 ± 0.38 |
The total IPSS is obtained by combining the scores of the responses to component questions 1 through 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Week 4 Change (n=184, 197, 183) | -3.4 ± 0.39 | -5.5 ± 0.38 | -2.6 ± 0.40 |
| Week 8 Change (n=174, 192, 178) | -4.5 ± 0.43 | -5.8 ± 0.41 | -3.8 ± 0.43 |
Self-reported erectile function over the past 4 weeks. Questions 1-5 were scored from 0-5, and Question 15 from 1 to 5. Erectile Function Domain scores range from 1 to 30; lower numerical scores represent greater severity of erectile dysfunction. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Week 4 Change (n=186, 197, 183) | 4.2 ± 0.44 | 6.1 ± 0.43 | 1.0 ± 0.45 |
| Week 8 Change (n=176, 192, 178) | 4.9 ± 0.49 | 6.6 ± 0.48 | 1.8 ± 0.52 |
Assessed as the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3, "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of yes responses per the number of sexual attempts for a participant during a study period. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| percentage of yes responses | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Week 4 Change (n=180, 190, 180) | 22.3 ± 2.31 | 30.7 ± 2.27 | 6.2 ± 2.35 |
| Week 8 Change (n=172, 187, 171) | 22.9 ± 2.16 | 31.7 ± 2.11 | 10.9 ± 2.21 |
The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Week 4 Change (n=186, 197, 183) | -1.0 ± 0.17 | -1.5 ± 0.16 | -0.7 ± 0.17 |
| Week 8 Change (n=175, 192, 177) | -1.4 ± 0.18 | -1.8 ± 0.17 | -1.2 ± 0.18 |
IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. The obstructive subscore ranges from 0 to 20 with a higher score representing greater obstruction. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score Voiding (Obstructive) Subscore at Week 12 Endpoint | -2.7 ± 0.28 | -3.6 ± 0.28 | -2.2 ± 0.29 |
IPSS irritative subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. The irritative subscore ranges from 0 to 15 with a higher score representing more irritative symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score Storage (Irritative) Subscore at Week 12 Endpoint | -1.9 ± 0.2 | -2.5 ± 0.19 | -1.6 ± 0.20 |
The IPSS Nocturia question (Question 7) measures the number of times needed to get up at night to urinate. Scores range from 0 (none) to 5 (5 or more times). Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score Nocturia Question at Week 12 | -0.5 ± 0.08 | -0.6 ± 0.07 | -0.5 ± 0.08 |
Assessment of quality of life (QoL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible). Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score Quality of Life (QoL) at Week 12 Endpoint | -0.9 ± 0.10 | -1.0 ± 0.10 | -0.8 ± 0.11 |
Self-reported overall satisfaction over the past 4 weeks. Calculated as the sum of IIEF Questions 13 and 14. Each question is scored from 1 through 5, with a possible total score of 2 through 10. Higher scores represent greater satisfaction. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in International Index of Erectile Function - Overall Satisfaction Domain at Week 12 Endpoint | 1.8 ± 0.16 | 2.4 ± 0.16 | 0.5 ± 0.16 |
Self-reported intercourse satisfaction over the past 4 weeks. Calculated as the sum of IIEF Questions 6, 7 and 8. Each question is scored from 0 through 5 with a possible total score of 0 through 15. Higher score represent greater satisfaction. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in International Index of Erectile Function - Intercourse Satisfaction Domain at Week 12 Endpoint | 1.6 ± 0.23 | 2.0 ± 0.22 | 0.2 ± 0.23 |
IIEF Question 3 asks how often a subject was able to penetrate his partner over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in International Index of Erectile Function Question 3 at Week 12 Endpoint | 0.9 ± 0.10 | 1.1 ± 0.10 | 0.2 ± 0.10 |
IIEF Question 4 asks whether how often a subject was able to maintain an erection after penetration over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in International Index of Erectile Function Question 4 at Week 12 Endpoint | 0.9 ± 0.11 | 1.3 ± 0.10 | 0.4 ± 0.11 |
Assessed as the mean change from baseline in the percentage of Yes responses to the SEP diary Question 2, "Were you able to insert your penis into your partner's vagina?" Data are presented as the mean percentage of yes responses per the number of sexual attempts for a participant during a study period. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| percentage of yes responses | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 2 at Week 12 Endpoint | 21.4 ± 1.82 | 25.1 ± 1.78 | 9.3 ± 1.84 |
Assessed as the mean change from baseline in the percentage of Yes responses to the SEP diary Question 4, "Were you satisfied with the hardness of your erection?" Data are presented as the mean percentage of yes responses per the number of sexual attempts for a participant during a study period. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| percentage of yes responses | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 4 at Week 12 Endpoint | 26.6 ± 2.48 | 39.4 ± 2.46 | 9.6 ± 2.61 |
Assessed as the mean change from baseline in the percentage of Yes responses to the SEP diary Question 5, "Were you satisfied overall with this sexual experience?" Data are presented as the mean percentage of yes responses per the number of sexual attempts for a participant during a study period. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, baseline covariate, baseline-by-treatment interaction and treatment-by-region interaction.
| percentage of yes responses | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 5 | 23.7 ± 2.49 | 38.2 ± 2.48 | 9.9 ± 2.63 |
A scale that measures the patient's perception of urinary symptoms at endpoint compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the seven categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).
| participants | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Very Much Worse | 0 | 0 | 1 |
| Much Worse | 3 | 2 | 4 |
| A Little Worse | 12 | 3 | 13 |
| No Change | 34 | 34 | 61 |
| A Little Better | 66 | 79 | 63 |
| Much Better | 57 | 60 | 37 |
| Very Much Better | 13 | 19 | 6 |
A scale that measures clinician's rating of the total change in the patient's urinary symptoms at endpoint compared with the start of treatment. Scores range from 1 (very much better) to 7 (very much worse).The data are presented as the number of participants in each of the seven categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).
| participants | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Very Much Worse | 0 | 0 | 1 |
| Much Worse | 2 | 1 | 4 |
| A Little Worse | 8 | 2 | 9 |
| No Change | 41 | 42 | 64 |
| A Little Better | 67 | 60 | 58 |
| Much Better | 56 | 78 | 45 |
| Very Much Better | 7 | 14 | 3 |
The EF-GAQ consisted of two questions: (1) Has the treatment you have been taking during this study improved your erections? and (2) If yes, has the treatment improved your ability to engage in sexual activity? Each question has a Yes/No response.
| participants with yes response | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Question 1 | 135 | 155 | 74 |
| Question 2 | 126 | 146 | 67 |
Qmax is defined as the peak urine flow rate (measured in milliliters per second \[mL/sec\] using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 milliliters (mL) and the voided volume (Vcomp) was \>= 125 mL.
| mL/sec | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Uroflowmetry Parameters - Peak Urine Flow Rate (Qmax) at Week 12 Endpoint | 1.7 ± 4.45 | 1.6 ± 4.15 | 1.2 ± 4.52 |
Qmean is defined as the average urine flow rate (measured in milliliters per second \[mL/second\] using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 milliliters (mL) and the voided volume (Vcomp) was \>= 125 mL.
| mL/sec | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Uroflowmetry Parameters - Mean Urine Flow Rate (Qmean) at Week 12 Endpoint | 1.0 ± 2.65 | 0.9 ± 2.92 | 0.6 ± 2.6 |
Vcomp is defined as the volume of urine voided (measures in mL using a standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 milliliters (mL) and the voided volume (Vcomp) was \>= 125 mL.
| mL | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Uroflowmetry Parameters - Voided Volume (Vcomp) at Week 12 Endpoint | 18.5 ± 113.9 | 13.3 ± 92.75 | 11.4 ± 91.84 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tadalafil 2.5 mg | — | 2/198 (1%) | 50/198 (25.3%) |
| Tadalafil 5 mg | — | 1/208 (0.5%) | 56/208 (26.9%) |
| Placebo | — | 1/200 (0.5%) | 38/200 (19%) |
| Event | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Myocardial infarctionCardiac disorders | 1/198 | 0/208 | 0/200 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/198 | 0/208 | 0/200 |
| Non-Hodgkin's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/198 | 0/208 | 1/200 |
| Pancreatitis haemorrhagicGastrointestinal disorders | 0/198 | 1/208 | 0/200 |
| Event | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 5/198 | 12/208 | 6/200 |
| NasopharyngitisInfections and infestations | 6/198 | 5/208 | 4/200 |
| Back painMusculoskeletal and connective tissue disorders | 1/198 | 6/208 | 3/200 |
| InfluenzaInfections and infestations | 4/198 | 1/208 | 5/200 |
| DyspepsiaGastrointestinal disorders | 1/198 | 3/208 | 0/200 |
| Upper respiratory tract infectionInfections and infestations | 0/198 | 3/208 | 0/200 |
| HypertensionVascular disorders | 0/198 | 3/208 | 1/200 |
| DiarrhoeaGastrointestinal disorders | 2/198 | 1/208 | 1/200 |
| BronchitisInfections and infestations | 2/198 | 0/208 | 1/200 |
| SinusitisInfections and infestations | 2/198 | 1/208 | 2/200 |
| Age Continuous(years) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 62.2 ± 7.56 | 62.5 ± 8.43 | 62.9 ± 8.23 | 62.6 ± 8.08 |
| Sex: Female, Male(Participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 198 | 208 | 200 | 606 |
| Ethnicity (NIH/OMB)(Participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 33 | 31 | 30 | 94 |
| Not Hispanic or Latino | 165 | 177 | 170 | 512 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 6 | 6 | 2 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 9 | 6 | 8 | 23 |
| White | 181 | 194 | 190 | 565 |
| More than one race | 1 | 2 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| France | 17 | 24 | 21 | 62 |
| Portugal | 8 | 3 | 6 | 17 |
| United States | 71 | 71 | 68 | 210 |
| Mexico | 27 | 27 | 22 | 76 |
| Canada | 22 | 23 | 26 | 71 |
| Greece | 7 | 9 | 9 | 25 |
| Russian Federation | 21 | 29 | 25 | 75 |
| Germany | 10 | 12 | 9 | 31 |
| Italy | 15 | 10 | 14 | 39 |
| Body Mass Index (BMI)(kg/m²) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 27.7 ± 3.86 | 28.0 ± 4.18 | 28.6 ± 4.8 | 28.1 ± 4.3 |
| Lower Urinary Tract Symptoms (LUTS) Severity(participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Moderate (IPSS <20) | 123 | 124 | 122 | 369 |
| Severe (IPSS ≥20) | 74 | 84 | 78 | 236 |
| Unknown | 1 | 0 | 0 | 1 |
| Peak Urine Flow Rate (Qmax)(participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| <10 mL/sec | 96 | 87 | 99 | 282 |
| 10-15 mL/sec | 73 | 83 | 66 | 222 |
| >15mL/sec | 21 | 16 | 16 | 53 |
| Unknown | 8 | 22 | 19 | 49 |
4 further baseline measures are reported on the registry.
The record gives a start of Mar 2009, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil